Entera Bio Ltd. has made a significant leadership change by appointing Laura Hamill to its Board of Directors. This decision, filed on October 6, 2026, under Form 8-K (accession number 0001178913-26-004720), is noteworthy as it reflects the company's ongoing commitment to enhancing its strategic direction and commercial expertise.
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. The company focuses on developing oral peptide and protein replacement therapies aimed at addressing significant unmet medical needs. Their innovative approach leverages a proprietary technology platform, N-Tab®, which enables the development of oral medications that could transform standard care practices.
Details of the Filing
The filing reveals that Laura Hamill will officially join the Board as a Class I director on December 1, 2026. She will serve until the Company's 2027 Annual Meeting of Shareholders, or until her successor is elected. Alongside her directorial role, Ms. Hamill will also be a member of the audit committee and the corporate governance and nomination committee.
Ms. Hamill, who is 62 years old, brings over 35 years of experience in the biopharmaceutical industry. She previously held the position of Executive Vice President at Gilead Sciences, where she oversaw worldwide commercial operations. Her extensive background also includes nearly two decades at Amgen, where she held various leadership roles, including Senior Vice President of U.S. Commercial Business Operations.
"I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution," said Miranda Toledano, CEO of Entera.
In her new role, Ms. Hamill will participate in the company's standard non-employee director compensation arrangements, which were recently approved by shareholders. This includes annual cash payments for board service and annual equity grants under the company's 2018 Equity Incentive Plan.
Impact of the Changes
The appointment of Laura Hamill is expected to enhance Entera's leadership team as the company advances its clinical pipeline, particularly with its lead product candidate, EB613, aimed at treating osteoporosis. This change may positively influence the company's strategic direction and operational effectiveness, particularly as it prepares for late-stage clinical trials.
The filing also notes the departure of Yonatan Malca from the Board, effective December 1, 2026. His resignation was not due to any disagreement with the company, indicating a smooth transition in leadership.
What's Next?
The filing does not specify what happens next, but it highlights the company's ongoing efforts to strengthen its governance and operational capabilities as it moves forward with its clinical programs.